THIS IS EXPORT. THIS IS WALES.

BIO INTERNATIONAL CONVENTION 2026

Export Market Visit | 20–26 June 2026 | tradeandinvest.wales

San Diego Marina, California

This is Export.
This is Wales.

Bio International Convention 2026

Export Market Visit to USA

Pierhead, Senedd and
Wales Millennium Centre, Cardiff Bay

Wales is a self-governing constituent country of the UK and the Welsh Government is the devolved Government for Wales.

Devolved since 1999, the Welsh Government's decision-making powers within a small and joined-up country mean we can cut red-tape and act fast.

They also mean we are responsible for our own economic development, working with business to create a prosperous, green and equal economy.

Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. We have strength in depth in advanced manufacturing, creative industries, energy and environment, financial and professional services, food and drink, life sciences, and technology.

Our commitment to sell Wales to the world has never been more focussed and this mission provides an ideal platform for us to build on established links and discuss future export opportunities.

Wales means business.

Blackwood Embedded Solutions is an expert in the design of electronic products for a broad range of sectors, including medical, automotive, finance and consumer.

The company has a proven track record of getting clients to market within the shortest time possible, and they return to work with Blackwood Embedded Solutions time and time again.

With a high percentage of clients in the medical sector, Blackwood Embedded Solutions works to exacting regulatory standards which result in more robust products.

Blackwood Embedded Solutions works to ensure that all production level embedded code is produced to MISRA guidelines.

Blackwood Embedded Solutions has a keen eye for quality and is ISO 9001 accredited but can also work within clients' quality management systems (e.g. ISO 13485). Support can be provided in risk analysis and FMEA analysis throughout the design process to meet the ISO 14971 standard.

Blackwood Embedded Solutions often develops hardware and software in parallel to meet tight deadlines. The company is also happy to work collaboratively with other design agencies as appropriate to deliver the best outcome for the client.

Product/Service

Electronics and software R&D for medical devices.

Objectives

Seeking new medical electronic and software design projects to work on.

Anthony Giles
Managing Director

+44 (0)2922 401 314
anthony.giles@blackwoodembeddedsolutions.co.uk

www.blackwoodembeddedsolutions.co.uk

Spun out of AstraZeneca in 2010, **CatSci** is an award-winning innovation partner, dedicated to breaking down silos in drug development to accelerate the delivery of life-changing medicines.

They proudly serve customers across the globe, delivering perfect-for-purpose solutions that balance timelines and resources with maximum flexibility.

Product/Service

CatSci's tailored services span route scouting, selection, scale-up, and risk management for early development. In later stages, they deliver process design, optimisation, scale-up for clinical and commercial manufacture, technology transfer, and post-approval improvements. Their specialist capabilities include Process R&D, catalysis, high-pressure reactions, crystallisation, preformulation, analytical and HPAPI development, alongside oligonucleotide, peptide, and bioscience expertise. Through their partnership with AGC Pharma Chemicals, they provide scalable small molecule API manufacturing – from grams to tonnes – with full accountability for technology transfer.

Objectives

CatSci's overall mission is to enable customers to create innovative therapeutics that will improve patient quality of life. They aim to become a 'digital first, intelligent automation next' business, freeing up the hands and minds of scientists through digital tools, enabling them to create perfect-for-purpose solutions that solve customers' problems. Their purpose is and always will be to get medicines into the hands of patients in need.



Dr Simon Tyler
Chief Commercial Officer

+44 (0)3300 250 170
simon.tyler@catsci.com

Jas Douville, Ph.D.
Vice President of Business Development

+44 (0)3300 250 170
jas.douville@catsci.com

www.catsci.com

As part of the UK's world-leading life sciences ecosystem, Wales offers a fast, agile, and collaborative environment for industry-sponsored research.

Ymchwil Iechyd a Gofal Cymru
Health and Care Research Wales

With substantial health needs and strong integration and collaboration between health services across primary and secondary care, Wales can set up studies fast and recruit strongly to research across a range of health areas. Wales is building on these strengths through a renewed national focus on industry collaboration, backed by strong commitment from Welsh Government and NHS Wales leadership and targeted investment in leading research centres.Health and Care Research Wales is a Welsh Government funded organisation. They bring together a range of partners across the NHS, universities, research institutions, and the third sector to support this ambition – making Wales an accessible and responsive partner for commercial research.

Product/Service

Health and Care Research Wales can provide coordinated points of entry, consolidated information, and ongoing support and partnership to bring research to Wales. This can include connections with leading clinical experts, co-ordinated set up across multiple sites, proactive performance management of study set-up and recruitment, and national oversight and central points for escalation and problem-solving. These services are led by a national team and can facilitate timely and efficient access to experts and potential research sites across Wales.

Objectives

Health and Care Research Wales is aiming to showcase Wales' strengths as a destination for industry-sponsored research, highlight support available for delivering research in Wales, and build connections with companies who could benefit from these services.

Gareth Hopkin
Head of Commercial
Research Delivery Wales

+44 (0)2920 230 457
gareth.hopkin@wales.nhs.uk

Jamie Duckers
Consultant in Respiratory Medicine, Specialty Lead for Respiratory in Wales, National Clinical Lead for Rare Diseases in Wales

+44 (0)2920 230 457
jamie.duckers@wales.nhs.uk

www.healthandcare researchwales.org

For over 30 years, **PDR Design** has been designing distinctive, successful, and award-winning products for innovative organisations — from ambitious startups to global blue chip companies.

PDR Design partner with organisations that recognise that doing more of the same is no longer enough. Today's fast moving markets demand change, innovation, and products that are intelligent, connected, functional, personalised, and beautifully crafted. PDR Design helps clients meet these expectations by combining creative design thinking with deep technical expertise and evidence led decision making. With hundreds of successful products delivered — from consumer goods to complex, life critical medical devices – PDR Design provides the full spectrum of product design services needed to take an idea from its initial conception through to market launch and beyond. PDR Design's multidisciplinary capabilities span design research, concept generation, UX and human factors testing, engineering, prototyping, and support for manufacture. Trusted by many of the world's leading brands, PDR Design is known for creating solutions that connect deeply with users and challenge established market norms. PDR Design's projects are consistently delivered on time, within budget, and with outcomes that exceed expectations. As an internationally recognised design consultancy, PDR Design continues to help organisations innovate with confidence and deliver products that stand out in competitive global markets.

Product/Service

Medical Device Design, Human Factors and Usability Engineering, GUI Design, User Centred Design, Product Design, Industrial Design, Service Design, Consumer Insight Research, New Opportunity Identification and Execution.

Objectives

To connect with partners and innovative organisations seeking expert support in developing new products, services, and user experiences for both domestic and international markets.

Jarred Evans
Director

+44 (0)7887 734 804
jwevans@pdr-design.com

Rae DePaul
Research & Innovation Grants & Contracts Manager

rdepaul@cardiffmet.ac.uk

www.pdr-design.com

Reacta Healthcare is a specialist manufacturer of clinical trial materials for food allergy.

Operating from a UK MHRA-licensed facility, the company produces GMP-grade products designed specifically for use in oral food challenge studies. Reacta supports global pharmaceutical and biotechnology companies in the development of food allergy therapies by enabling the safe, standardised and regulator-ready assessment of patient responses. With experience supporting programmes across Europe, the US and Asia, Reacta brings deep expertise in clinical trial requirements, allergen standardisation and regulatory expectations.

Product/Service

Reacta manufactures oral food challenge materials for use in double-blind placebo-controlled food challenge trials, widely regarded as the gold standard for assessing food allergy. Products are developed and produced under GMP conditions, with robust characterisation, defined specifications and stability data to support regulatory submissions. The company offers a range of age-appropriate formulations across key allergens including peanut, milk and egg, with additional allergens in development. Reacta's approach is designed to reduce operational complexity, improve consistency across sites and support efficient trial delivery.

Objectives

At BIO 2026, Reacta aims to engage with pharmaceutical and biotechnology companies developing therapies in food allergy and broader immunology. The focus is on establishing new partnerships, supporting upcoming clinical programmes and positioning Reacta as a strategic partner for oral food challenge delivery. The company is also seeking to expand its presence in the US market and build relationships with CROs and clinical networks involved in allergy trials.

David Brand
Business Development Manager

+44 (0)7500 901 214
david.brand@reactahealthcare.com

Andrea Cherbonnier
Client Relations Manager

+44 (0)3332 423 036
andrea.cherbonnier@reactahealthcare.com

www.reactahealthcare.com

SGS CDMO Solutions is a specialist pharmaceutical development and manufacturing organisation with over 20 years of experience supporting clients from early formulation through to clinical and commercial supply.

Operating from a state-of-the-art, MHRA- and FDA-compliant facility in Deeside, North Wales, the company employs circa 104 highly skilled scientists, pharmacists, engineers and technical specialists. SGS Quay Pharma provides expertise in complex formulation development, including oral solid dose, liquids, semi-solids and live biotherapeutic products. The company offers fully integrated services across pre-formulation, analytical development, GMP clinical manufacturing, packaging and global clinical supply. As a licensed manufacturer, SGS produces and supplies medicinal products for clinical use worldwide and is recognised as a trusted partner for end-to-end drug development and clinical manufacturing.

Product/Service

SGS CDMO Solutions intends to promote and sell its full suite of specialist pharmaceutical development, manufacturing and clinical trial services within the US market. This includes:

—Complex formulation development for oral solid dose, liquid, semi-solid and live biotherapeutic products.
—GMP clinical manufacturing of medicinal products, including global packaging, labelling and clinical supply.
—Analytical and stability services supporting regulatory submissions for MHRA, FDA, EMA and international authorities.
—End-to-end clinical trial support, including study design, regulatory preparation, site and patient sourcing, trial set-up, and product supply management.
—Global medicinal product supply for clinical use.

Objectives

The overall objective of this project is to expand SGS' international commercial presence in the United States by establishing high-value partnerships with pharmaceutical and biotechnology organisations, clinical research organisations, and innovation hubs. The visit aims to promote SGS' full suite of end-to-end services, including complex formulation development, GMP clinical manufacturing, analytical and regulatory support, and clinical trial management, to companies that lack inhouse capabilities or require specialised expertise.

Nicholas Weeks
Business Development Manager

+44 (0)7557 284 307
nicholas.weeks@sgs.com

www.sgs.com/cdmosolutions

Simbec-Orion is a specialized, full-service global CRO supporting biotech and biopharma companies from early clinical development through multinational registrational studies.

SIMBEC-ORION

Established in 1976, we bring 50 years of clinical development experience across oncology, rare and orphan diseases, clinical pharmacology, neurology, metabolic disorders, autoimmune diseases, and advanced therapies. Headquartered in Merthyr Tydfil, Wales, home to our fully integrated, MHRA-accredited Phase I Unit, Simbec-Orion operates from 10 global office locations, including our newly opened U.S. office in Cambridge, Massachusetts. Our experienced teams span 38 countries, with operational reach across North America, the UK, Western and Eastern Europe, and APAC.

Product/Service

Simbec-Orion provide tailored clinical development solutions designed around each sponsor's program, from IND-enabling support and first-in-human studies to pivotal Phase II/III multinational trials.
The company's integrated services include clinical development strategy, project management, regulatory affairs, medical affairs, pharmacovigilance, site management, monitoring, medical writing, biometrics, bioanalytical and central laboratory services, IMP management, PK/PD, bioavailability and bioequivalence studies, scintigraphy, and full-service clinical trial delivery.

Objectives

At BIO International 2026, Simbec-Orion is looking to meet biotech, biopharma, and pharma partners advancing programs in oncology, rare and orphan diseases, neurology, metabolic, autoimmune, and advanced therapies. Simbec-Orion welcome conversations with companies planning studies now or in the future, from IND-enabling work through Phase III registrational trials. Where aligned, the company can also support introductions across our investor, advisor, and KOL network. Meet with Simbec-Orion at BIO International 2026 to discuss how its global CRO team can support your clinical development strategy.

Dustin M. Hawley
Vice President, Business Development, North America

+1 (609) 454-2222
dustin.hawley@simbecorion.com

Nikola Strumberger
Chief Commercial Officer

+39 (338) 103 6902
nikola.strumberger@simbecorion.com

www.simbecorion.com

The Science Behind provides specialist neuroscience technologies and capabilities to biotechs and clinical contrac t research organizations (CROs) in early-phase clinical trials for neurodegenerative and central nervous system disorders.

The company aims to become the preferred partner for those requiring specialist neuroscience expertise and technology for early-phase clinical trials.

Product/Service

Clinical trials for central nervous system diseases carry a high level of risk, and pharmaceutical companies face significant challenges in developing treatments. The Science Behind's team of neuroscience experts, combined with state-of-the-art technology and techniques, can provide objective and cost-effective methods for measuring drug effects. The company can help pharmaceutical companies answer key questions, such as whether the drug is crossing the blood-brain barrier, engaging with the right target in the brain, and what the best dose response is in terms of size and timing of efficacy. This additional insight can help pharmaceutical companies make more informed decisions and increase their chances of success in future clinical trials.

Objectives

The Science Behind seeks to meet with sponsors, ideally late-stage preclinical drug development or considering their first-in-human trials, and contract research organizations seeking to build capability to support central nervous system Phase 1 clinical trials. By working with The Science Behind, biotechs can tap into expertise in neuroscience to overcome the challenges associated with clinical trials for central nervous system diseases, ultimately leading to the development of effective treatments while reducing the risk and costs associated with failed trials.

Tonia Smreczak
Managing Director

+44 (0)2922 644 840
tonia@thesciencebehind.com

Soffia Cahill
Science and Partnership Manager

+44 (0)2922 644 840
soffia@thesciencebehind.com

www.thesciencebehind.com

Viamab Therapeutics is a biotechnology company developing a first-on-target antibody–drug conjugate (ADC) platform targeting the Receptor for Advanced Glycation End Products (RAGE).

Viamab Therapeutics

The lead programme is focused on oncology, with a primary indication in advanced colorectal cancer and additional data supporting ovarian, prostate, triple-negative breast cancer and broader pan-cancer potential. The company's goal is to create a targeted treatment option for patients who have few or no remaining treatment options available to them.

Product/Service

Viamab Therapeutics is a biotechnology company developing a first-on-target antibody–drug conjugate (ADC) platform targeting the Receptor for Advanced Glycation End Products (RAGE). The lead programme targets advanced colorectal cancer, with pipeline expansion planned across multiple RAGE-expressing solid tumour indications, including pancreatic, ovarian, triple-negative breast cancer and broader gastrointestinal cancers.

Objectives

Viamab Therapeutics is seeking investment and strategic partnerships – including out-licensing and co-development arrangements – to advance its lead programme through IND-enabling studies and into Phase 1 clinical trials. The company is targeting a $30 million raise: an initial $15 million to fund IND-enabling studies and initiate Phase 1, and a further $15 million to complete Phase 1.

Gareth Morgan
CEO

+44 (0)7866 558 314
gareth.morgan@viamab.com

www.viamab.com/

Decision making.

Wales is a connected country with a devolved Government for fast decision making from Ministers. The Senedd is home to our Welsh Parliament.

Nuvolt is a software-enabled energy infrastructure platform specialising in the delivery, optimisation and long-term operation of commercial and industrial energy assets.

Headquartered in Wales, the business combines intelligent energy monitoring, analytics and optimisation software with integrated infrastructure delivery capabilities across Solar PV, Battery Energy Storage Systems (BESS), EV charging and wider electrical infrastructure. Nuvolt's model integrates software, infrastructure deployment, long-term asset management and aligned funding solutions to support organisations in reducing energy costs, improving operational resilience and accelerating decarbonisation strategies. Alongside infrastructure delivery, Nuvolt provides long-term operate, monitor and maintain (O&M) services and works with commercial and industrial clients operating multi-site property portfolios across the UK.

Product/Service

—Energy monitoring, analytics and optimisation platforms
—Software-enabled asset performance solutions
—Energy-as-a-Service (EaaS) solutions
—Power Purchase Agreement (PPA) models
—Commercial and industrial Solar PV
—Battery Energy Storage Systems (BESS)
—EV charging infrastructure
—Long-term O&M and asset performance services
—Multi-site energy infrastructure deployment
—Aligned funding solutions for commercial energy infrastructure projects

Objectives

Nuvolt is attending the San Diego market visit to explore strategic partnerships, routes to market and investment opportunities within the US commercial and industrial energy sector, with a particular focus on software-enabled energy infrastructure and Energy-as-a-Service models.

The business is seeking relationships with strategic partners, facilities management providers, infrastructure operators, institutional investors and organisations with large multi-site property portfolios.

Matthew Phillips
CEO

+44 (0)7595 583 560
matthew.phillips@nuvolt.co.uk

www.nuvolt.co.uk

Founded in South Wales in 2018, **ZPE** have developed an advanced waste heat recovery systems that helps industry cut energy costs and carbon emissions.

Its proprietary AxialEnergy® technology converts wasted heat into clean electricity, recovering up to 15% of lost energy without disrupting existing operations. Designed as a flexible retrofit solution, the system improves plant efficiency, strengthens energy resilience, and supports decarbonisation and net-zero objectives across many energy-intensive industries. With rapid payback periods and scalable deployment, ZPE enables industrial operators to unlock value from wasted energy while reducing operating costs and environmental impact.

Product/Service

ZPEs patented AxialEnergy® steam engine technology captures industrial waste heat and converts it into AC or DC electricity through high-efficiency multi-cylinder steam engines coupled to alternators. Built for sectors including steel, cement, oil and gas and many manufacturing, and heavy industries, the technology integrates with existing infrastructure as a non-intrusive retrofit, system minimising downtime and operational disruption. ZPE offers flexible commercial models, including direct purchase, zero-capex structures, and power purchase agreements (PPAs), removing barriers to adoption while accelerating decarbonisation. Typical projects deliver strong operational savings with payback periods of one to three years. By transforming wasted heat into usable power, ZPE helps industrial clients improve efficiency, lower emissions, and strengthen long-term sustainability while giving energy security.

Objectives

ZPE's mission is to redefine industrial energy efficiency by turning wasted heat into valuable power. The company aims to help heavy industry reduce operating costs, improve energy performance, and accelerate the transition to lower-carbon operations. Through continuous innovation and scalable deployment, ZPE is expanding across global industrial sectors where waste heat represents a major untapped resource. By combining proven technology with flexible commercial delivery models, the company removes financial and operational barriers to adoption.
ZPE's objective is simple: deliver practical, commercially viable decarbonisation solutions that create measurable economic and environmental value for industry worldwide.

Paul Rebhan
Commercial Director

+44 (0)7379 919 386
paul@zpeltd.com

www.zpeltd.com

Find out what Wales can do for your business:
Tel: +44 (0)3000 603000
Web: tradeandinvest.wales

Linked-In: linkedin.com/showcase/trade-&-invest-wales
Facebook: facebook.com/InvestWales
Instagram: @InvestWales

Welsh Government Officials

Jonathan Fortune
Senior Manager, Export Services
jonathan.fortune@gov.wales

Claire Parfitt
International Trade Advisor
claire.parfitt@gov.wales

Overseas Offices – USA Los Angeles Office

Luis Calette
Head of West Coast USA
luis.calette@gov.wales
+1 (0) 213 662 3262

Christopher Koh
Deputy Head of West Coast USA
christopher.koh@gov.wales

Cymru Wales is the Welsh Government supported marketing initiative for Wales.

tradeandinvest.wales